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ABSTRACT 
Background: Hajj is the largest annual mass gathering; the risk of respiratory infection is high. 
Although the Saudi Arabian authority recommends influenza vaccination for Hajj pilgrims, the 
uptake is variable. Influenza vaccine uptake among Australian Hajj pilgrims is not readily 
available. Therefore we aimed to estimate the influenza vaccination uptake rate and identify both 
attitudes and barriers to vaccine uptake from two consecutives surveys at Hajj in 2011 and 2012. 
Methods: Using an anonymous self-administered questionnaire, surveys were conducted in 
Mecca, Saudi Arabia among Hajj pilgrims from Australia in 2011 and 2012. Pilgrims staying in 
‘Australian’ tents were recruited serially.  
Results: In 2011, 431 Australian pilgrims completed the survey - median age was 42 (range 7-
86) years, 55% were male; 65% reported receiving influenza vaccine. In 2012, 535 pilgrims 
median age 43 (range 12-83) years completed the survey, 62% were males; 89% reported 
receiving the vaccine. Both in 2011 and 2012, common reasons for not receiving the vaccine 
were the pilgrims’ reliance on their ‘natural immunity’ (33% and 26% respectively, p = 0.4) and 
believing that they would rarely catch influenza or come in contact with influenza patients (18% 
and 29% respectively, p = 0.1). In 2012 when asked why they had received the vaccine, 65% 
pilgrims responded that it was because of the tour group leaders’ recommendation. 
Conclusion: Influenza vaccine uptake among Australian Hajj pilgrims seems satisfactory and 
increasing but could be better because many pilgrims have misconceptions about vaccines. Tour 
operators may play a greater role in promoting vaccination. 
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Introduction  
Hajj is one of the five basic tenets of Islam. Every practising, financially and physically capable 
Muslim is required to perform Hajj at least once in their lifetime. Each year up to 3 million 
people from more than 180 countries assemble in Mecca, Saudi Arabia to perform Hajj 
pilgrimage. Severe crowding, shared accommodation, reduced personal hygiene and 
environmental pollution at Hajj may collectively lead to increased transmission of respiratory 
viruses, notably influenza.1-3  
Several months before each Hajj, the Saudi Arabian Ministry of Health (MoH) publishes health 
recommendations including vaccination requirements for pilgrims.4 Influenza vaccine has been 
recommended since 2005, particularly for people ‘at-risk’ of severe complications, defined as 
those aged ≥65 years old and/or people with pre-existing medical conditions such as chronic 
lung, heart, liver, kidney, neuromuscular, metabolic or immune-compromising conditions.4,5 
Despite this yearly recommendation, influenza vaccine uptake rate among Hajj pilgrims has 
varied by country and by year (see Table 1).6-13 
There are no comprehensive official data on influenza vaccination rate among Australian Hajj 
pilgrims or other travellers. A prospective study that assessed the incidence and risk factors for 
acute respiratory illnesses and influenza infections among Australian travellers between August 
2007 and January 2010, reported only 49% influenza vaccine uptake prior to their trip to Asia, 
and actually just 56% travellers admitted receiving the vaccine in the 3 years before travel.14 In a 
subsequent survey conducted among the students of the University of New South Wales, 
Sydney, Australia in 2010, intending to travel abroad, only 25% students reported ‘ever’ 
receiving an influenza vaccine.15  
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To this end, we have assessed the uptake of influenza vaccine, and examined the attitudes and 
barriers to, and perception of vaccination among Australian pilgrims who attended Hajj 
pilgrimage in 2 consecutive years, 2011 and 2012. 
 
Method 
Study participants 
The study surveyed a convenience sample of Australian pilgrims who assembled for Hajj 
pilgrimage in Mina (an important Hajj location at the outskirts of Mecca), Saudi Arabia, in 
November 2011 and October 2012. All pilgrims residing in Australian camps were approached 
serially according to tents and were invited to participate in this study. Only those who verbally 
consented were included.  
 
Study survey 
Between 4th and 9th November 2011, and between 24th and 29th October 2012, a survey was 
conducted using an anonymous self-administered structured questionnaire in Mina, Mecca to 
obtain participant’s demographics such as age, gender, postcode/suburb, tour group details, 
vaccination status and examine the participant’s perceptions of influenza vaccination. 
For the 2011 survey, we included history of influenza vaccination in 2009 (monovalent 
pandemic) and 2010 (trivalent seasonal) and where the vaccine had been administered. In the 
2012 questionnaire, reasons for receiving the vaccine were added but the place of vaccine   
administration was deleted. The questionnaire in both years (2011 and 2012) was piloted among 
staff of the National Centre for Immunisation Research and Surveillance (NCIRS) prior to the 
study. 
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Twenty six trained volunteer researchers conducted the Hajj studies, answering questions and 
providing explanations as required. Questionnaires were collected within 30 minutes. The tour 
group guides arranged broadcasts about the study in English and Arabic. For those pilgrims who 
could not complete the questionnaires or preferred not to, volunteer researchers recorded dictated 
answers. 
 
Ethics Approval 
The study was approved by the Human Research Ethics Committee (HREC) at Sydney 
Children’s Hospital Network, Australia (Ref: 11/SCHN/162). 
 
Data analysis 
Analysis was performed using statistical Package for the Social Sciences (IBM SPSS® 19, 
Chicago, IL, USA). Categorical variables were compared by using Chi-square test and 
continuous data by Student’s t test, and where appropriate multivariate analysis was done by 
using multinomial logistic regression to assess demographic and socio-economic influences on 
vaccine uptake. A p value ≤ 0.05 was considered statistically significant.  
 
Results 
The 2011 Survey 
Demographics  
In 2011, about 4,200 Australian pilgrims assembled for Hajj; 442 (11%) were serially 
approached and 431 (98%) completed the questionnaire (Fig. 1), 235 (55%) were male, 187 
(44%) female and in 9 (2%) gender was not stated. Age or date of birth was obtained from 417 
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(97%) pilgrims aged between 7 and 86 (median 42) years. Females were slightly older than 
males (mean age 43 {standard deviation [SD 15] versus 41 [SD 14]} years, p = 0.05) while the 
proportion of ‘at-risk’ pilgrims was similar in both gender groups (20% versus 22%, p = 0.7).  
Half of the participants (n=217) were from New South Wales (NSW), a third (n=143) were from 
Victoria and the rest 17% (n=71) were from other Australian states and territories, reflecting a 
representative sample of Muslims based on their place of residence in Australia.16  
Saudi Arabian Hajj regulations require that every Hajj pilgrim must travel to Mecca through a 
registered tour group. Our study participants travelled to Hajj through 16 different tour groups. 
The largest proportion of the respondents belonged to tour group ‘A’ (n=104, 24%) and the rest 
belonged to one of 15 ‘other tour groups’ ranging in size from 1 to 81.     
Ninety one pilgrims (21%) were ‘at-risk’ (n=61, 67% with chronic medical conditions, n=12, 
13% aged ≥65 years and n=18, 20% with both). Fifty one (56%) of them were male and 38 
(42%) female; gender was unknown for 2 (2%).  
Vaccine uptake  
Of 431 pilgrims, 278 (65%) reported receiving influenza vaccine in 2011. The vaccination rate in 
pilgrims from NSW was significantly lower than those from the other states and they were 
younger (mean age: 40 [SD 15] versus 44 [SD 14] years, p < 0.01). However, they had a similar 
proportion of pilgrims with risk conditions (19% versus 23%, p = 0.37). Uptake rates by those 
aged ≥65 years from NSW and from other states were similar (73%). 
The vaccination rates by age groups, ‘at-risk’ conditions and tour groups are shown in Table 2.  
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‘Not at-risk’ females had higher vaccination rate compared to ‘not at-risk’ males (73% versus 
56%, p < 0.01), but for the ‘at-risk’ groups (76% versus 69%, p = 0.43) the difference was not 
significant.  
Of the 278 vaccinated pilgrims in 2011, 244 (88%) reported receiving the vaccine from their 
GPs, 13 (5%) from hospitals, 11 (4%) at their work place, 7 (3%) at other places including travel 
clinics and the remaining 3 (1%) did not specify the place of vaccination.  
Of 153 non-vaccinated pilgrims, 142 (93%) provided reasons for not being vaccinated; the 
reasons are listed in Table 3.   
One hundred and forty two (33%) reported receiving the monovalent pandemic vaccine in 2009, 
whereas 268 (62%) did not, and the remaining 21 (5%) Hajjis did not answer the question. One 
hundred and twenty five (29%) reported receiving seasonal vaccine in 2010, 293 (68%) did not, 
and the rest 13 (3%) did not answer. Receiving the pandemic vaccine in 2009 and the seasonal 
vaccine in 2010 doubled the likelihood of receiving influenza vaccine in 2011 (OR 2.2; 95% CI 
1.2 – 4.0; p < 0.01and 2.1 95% CI: 1.1 – 3.9; p = 0.02 respectively).  
 
The 2012 Survey 
Demographics  
In 2012, about 4,000 Australian pilgrims congregated at Hajj; 553 (14%) of these were 
approached and 535 (97%) completed the questionnaires (Fig. 1), 334 (62%) were male, 182 
(34%) female and in 19 (4%) gender was not stated. Age or date of birth was obtained from 506 
(95%) pilgrims aged between 12 and 83 (median 43) years.  
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The distribution of residency in this survey was comparable to the 2011 survey with 40% (n= 
216) participants from NSW, 36% (n=192) from Victoria and the rest 25% (n=133) from other 
Australian states and territories. Participants travelled to the 2012 Hajj through 13 different tour 
groups. As in 2011, the largest proportion of the participants were from tour group ‘A’ (n=111, 
21%) and the rest belonged to one of 12 ‘other tour groups’.     
One hundred pilgrims (19%) were considered ‘at-risk’ due to the presence of one or more 
indications for vaccination including chronic medical conditions (n=83, 83%), age ≥65 years 
(n=17, 17%) or both (n=16, 16%); 62 (62%) were male and 37 (37%) female and the gender of 
one pilgrims ‘at-risk’ (1%) was unknown.  
Vaccine uptake 
Of 535 participants, 476 (89%) reported receiving influenza vaccine in 2012, 42 (8%) did not 
receive the vaccine and in 17 (3%) vaccination history was not stated. The uptake rate was 
similar in both genders, across the states and tour groups (Table 2).  
Of 42 non-vaccinated pilgrims, 32 (76%) provided reasons for not being vaccinated; the reasons 
are listed in Table 3. Recommendation of the Hajj tour group leader was the commonest reason 
(65%) for pilgrims’ vaccine uptake; other reasons are listed in Table 4.  
 
Discussion  
We have shown evidence for a much greater uptake of influenza vaccine among Australian Hajj 
pilgrims in 2012 compared to 2011. Also, prior history of receiving influenza vaccine in 2009 
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and/or 2010 was associated with an increased likelihood of receiving the vaccine in 2011. Some 
Hajj pilgrims still have misconceptions about influenza vaccine, however.  
As in this study, other surveys conducted among older Australian residents also show an 
increased influenza vaccine uptake.17, 18 The coverage rate of 89% in 2012 among Australian 
Hajj pilgrims compares well with the vaccination rate among the Iranian pilgrims (86%-98%) for 
the last few years, and French (97%) and domestic Saudi pilgrims (94%) for the 2009 Hajj.7, 11, 13, 
19, 20 It was higher than among US (63%) and Malaysian (73%) pilgrims.6, 21 A cross-sectional 
survey conducted several years ago among Asia-Pacific travellers, including Australians, showed 
that only 3% of ‘Western’ (i.e., those from Australia, New Zealand, Europe and North America) 
travellers received influenza vaccine for their trip and 11% received the vaccine in previous 
years. However, specific data for Australian travellers were not shown.15 Specific data on 
influenza vaccination uptake among Australian travellers to Asia and student travellers to 
international destinations show that the uptake rate is generally between 25% and 49%.14  
However, vaccine uptake among Australian travellers and Hajj pilgrims (found in this survey) is 
better than for some other developed countries such as the UK where a recent survey found that 
only 20.8% travellers reported having influenza vaccine over the preceding 5 years.22  
 
In our 2011 survey, pilgrims who had received influenza vaccine previously had a higher vaccine 
uptake. Systematic reviews have consistently confirmed that receiving a prior seasonal influenza 
vaccination is an important determinant of both pandemic and seasonal influenza vaccination.23-
25 This fact was examined by Shahrabani and Benzion through the use of an analytical model 
based on four dependent variables: beliefs about susceptibility to contracting influenza, severity 
of illness, perceived benefits of the vaccine in preventing influenza, and perceived barriers to 
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getting vaccinated. The investigators found out that individuals who had ‘flu shots’ in the past 
perceived higher levels of benefits from the vaccine and lower barriers to getting the vaccine 
than those who had not been vaccinated, while those who had had influenza infection over the 
previous 2 years exhibited higher levels of perceived susceptibility and lower levels of perceived 
benefits from the vaccine. Health beliefs regarding the influenza vaccine and past illness seem to 
influence vaccine acceptance, but not always predictably.26 This helps explain why pilgrims 
receiving influenza vaccine previously had a significantly higher uptake than those who missed 
it.  
 
Misconceptions were common among Hajj pilgrims who did not receive the influenza vaccine. 
Reliance on ‘natural immunity’ was the main reason given for not receiving the vaccine in 2011 
and 2012. While our survey did not distinguish between reliance on the body’s general immune 
competence and immunity resulting from past infection with influenza, it did expose a lack of 
understanding of the need for annual influenza vaccination. A recent Australian national survey 
has demonstrated that the three most cited reasons by those aged ≥65 years for refusing 
vaccination were: ‘I don’t get the flu’, ‘I’m not at-risk’, and ‘It brings on the flu’ 27, paralleled by 
some Hajj pilgrims. Memish and colleagues reported that lack of awareness and knowledge 
about the access to vaccine were the two most important reasons for not receiving seasonal 
influenza vaccine among international pilgrims during the Hajj 2009.7 Misperceptions about 
pandemic influenza vaccine have also been reported among health care workers (HCWs) 
deployed at Hajj in 2009 when over half refused the vaccine mainly because of a belief that 
pandemic influenza was not fatal and there were toxic preservatives in the vaccine.28 In a 
previous survey conducted among Asia-Pacific travellers including Australians, 27% believed 
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that they were not at risk of influenza and another 14% thought that influenza vaccine was not 
important.29 A USA survey also confirms that many travellers avoid influenza vaccination due to 
misperceptions such as thinking that they do not need the vaccine and fearing of being ill from 
the vaccine or of needles etc.30 It is reassuring that in our study no Hajj pilgrim refused the 
vaccine on ‘religious grounds’. However, this study indicated that recommendations of religious 
leaders like Imams and tour group leaders were important in enhancing the uptake of influenza 
vaccine among pilgrims. A study in the UK showed that religious leaders–such as Imams and 
Quran teachers are “important drivers of health promotion measures”.31   
In 2011 females had significantly higher vaccine uptake than males which corresponds with 
Australian national influenza vaccination data.27 A Dutch study involving Hajj pilgrims in 2001 
to 2009 showed similar gender difference for diphtheria, tetanus and pertussis (DTP) vaccine 
uptake.32 However, a gender difference was not observed in the 2012 survey, neither were there 
differences across tour groups or Australian states when many more people accepted vaccination. 
Moreover, there were differences in vaccination rates across tour groups and Australian states 
which were not found in the 2012 survey, implying that such a difference was peculiar to the 
year 2011 only, and the differences disappeared when the overall vaccination rate improved in 
2012.  
A strength of this study is that it is the first to investigate influenza vaccine uptake among 
Australian Hajj pilgrims and one of the few studies to assess vaccine uptake among Australian 
travellers, and the study is representative of Muslims throughout Australia. Surveys were 
completed and collected within 30 minutes after Hajjis had opportunity to clarify questions; we 
achieved a very high (97%) response rate. However, the study has some limitations: being an 
anonymous survey, GP vaccination records could not be used for verification of vaccination or 
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co-morbid conditions. Additionally, some data were missing as some questionnaires were only 
partially completed (for instance about 3.5% pilgrims did not disclose their age and gender). 
Level of education and occupation could influence pilgrims’ perception about influenza vaccine, 
but these data were not collected. Finally, our findings may not be generalisable to ordinary 
travellers due to the distinctive characteristics of Hajj pilgrims and the religious nature of the 
event. 
In summary, this survey shows that many more Australian pilgrims (89%) received influenza 
vaccine in 2012 perhaps due to a combination of tour group leaders’ recommendation, awareness 
about the availability of influenza vaccine and an increased perception of risk, even though 
misperceptions about influenza vaccine were frequent. Targeted education of pilgrims, and 
maximizing the preventive role of tour group leaders underpinned by good continuing 
surveillance could improve the vaccination acceptance and rates.   
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Figure legend 
 
Figure 1   Flow diagram showing recruitment of participants  
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Table 1  Summary of studies showed influenza vaccine uptake among pilgrims from different 
countries in different Hajj years.  
Authors Study settings Study type Study 
year 
Influenza 
vaccine 
uptake % 
Meysamie et 
al11 
Pre-travel clinical and para-clinical 
assesment followed up by a survey 
during Hajj in Mecca 
Cohort 2004 and 
2005 
88 
Rashid et al9 British Hajj Delegation (BHD) 
clinics in Mecca and Mina  
Cohort 2005 28 
Alborzi et al13 Post-travel surveillance among 
pilgrims arrived from Hajj at Shiraz 
airport 
Cross-section 2006 86 
Rashid et al12 BHD clinics in Mecca and Mina  Cohort 2006 37 
Rashid et al12 National Guard Health Affairs 
clinics in Mina  
Cohort 2006 4 
Gautret et al10 Pre-travel and post-travel surveys 
for the same participants in travel 
clinics followed up by telephone 
interview 
Cohort 2007 27 
Balaban et al6 Pre-travel and post-travel surveys 
for the same participants in travel 
clinics, mosques, community 
clinics and at airport  
Cohort 2009 63 
Gautret et al7 Pre-travel and post-travel surveys 
for the same participants in travel 
clinics followed up by telephone 
interview 
Cohort 2009 97 
Memish et al8 2 separate surveys during arrival 
and departure of pilgrims at Jeddah 
airport  
Cross-section 2009 53 
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Table 2  Influenza vaccine uptake rates according to gender, residential address, risk status and 
previous years’ vaccination   
Characteristics Vaccine uptake in 
2011 n (%) 
Vaccine uptake in 
2012 n (%) 
p Value* 
Gender†  
Male 138 (59) 297 (88) <0.01 
Female 136 (73) 162 (89) <0.01 
State of residence‡   
New South Wales 123 (57) 196 (91) <0.01 
Other states including Victoria 155 (72) 241 (89) <0.01 
Age and risk status 
‘At-risk’  66 (73) 93 (93) <0.01 
‘Not at-risk’ 212 (62) 383 (88)  <0.01 
Age ≥65 22 (73) 31 (94) <0.01 
Age <65 with chronic medical 
conditions 
43 (73) 58 (92) <0.01 
Age <65 without chronic 
medical conditions 
207 (63) 366 (89) <0.01 
Tour groups 
Pilgrims in tour group ‘A’§          41 (39) 104 (94) <0.01 
Pilgrims in ‘other tour groups’ 237 (73) 359 (89) <0.01 
 *p value is for the difference in vaccine uptake between 2011 and 2012, calculated by Chi-
square test. 
†Gender was not known for 9 subjects in 2011 and 17 in 2012. 
‡State of residence was not reported for 39 pilgrims. 
§Hajj tour group ‘A’ is a group with the largest proportion of the respondents. 
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Table 3   Reported reasons for not receiving influenza vaccine in 2011 and 2012 
Reasons for not receiving the vaccine Respondents n* (%) 
in 2011 
Respondents* n (%) 
in 2012 
p Value†  
Reliance on natural immunity 50 (33) 11 (26) 0.4 
Believing that they rarely get influenza 28 (18) 12 (29) 0.1 
Too busy to get the vaccine 20 (13) 7 (17) 0.5 
Not aware of the availability of flu vaccine 19 (12) 0 0.02 
Don’t like injections  13 (8) 0 0.05 
Fear of side effects  10 (7) 1 (2) 0.3 
Believing that the vaccine doesn’t work  10 (7) 2 (5) 0.7 
Thought that vaccine gives flu  9 (6) 2 (5) 0.8 
They had to pay  9 (6) 1 (2) 0.4 
They took it in previous years year  8 (5) 2 (5) 0.9 
Got flu from the vaccine in the past 6 (4) 0 0.2 
Other reasons 14 (9) 1 (2) 0.1 
*Participants reported more than one reason. 
†Calculated by Chi-square test. 
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Table 4   Reasons for receiving influenza vaccine in 2012  
Reasons for being vaccinated Respondents* n (%) 
Recommended by Hajj tour group 311 (65) 
Because flu is a serious disease 162 (34) 
Recommended by doctor  144 (30) 
Recommended by a friend  55 (12) 
To protect family  47 (10) 
Vaccine is offered at workplace 43 (9) 
Working with vulnerable people  31 (7) 
Considering themselves “at-risk” 17 (4) 
Because of travel to Hajj 15 (3) 
Other reasons 12 (3) 
*Most participants reported more than one reason. 
 
 
